Multicenter study of high-dose daptomycin for treatment of enterococcal infections

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 9, 2013, Pages 4190-4196

  Casapao, Anthony M ^a   Kullar, Ravina ^b   Davis, Susan L ^a,c   Levine, Donald P ^d,e   Zhao, Jing J ^a,f   Potoski, Brian A ^g,h   Goff, Debra A ^i,j   Crank, Christopher W ^k   Segreti, John ^k   Sakoulas, George ^l   Cosgrove, Sara E ^m,n   Rybak, Michael J ^a,d  

^a WAYNE STATE UNIVERSITY   (United States)

^b OREGON STATE UNIVERSITY   (United States)

^c HENRY FORD HOSPITAL   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e DETROIT RECEIVING HOSPITAL   (United States)

^f HARPER UNIVERSITY HOSPITAL   (United States)

^g UNIVERSITY OF PITTSBURGH   (United States)

^h PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

ⁱ THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^j OHIO STATE UNIVERSITY   (United States)

^k RUSH UNIVERSITY MEDICAL CENTER   (United States)

^l UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^m JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ JOHNS HOPKINS HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; DAPTOMYCIN;

ABDOMINAL INFECTION; ADULT; AGED; ANTIMICROBIAL THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIUM ISOLATE; BLOOD CULTURE; BONE INFECTION; CATHETER INFECTION; DISEASE ERADICATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; FEMALE; HUMAN; INFECTIOUS ARTHRITIS; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTICENTER STUDY (TOPIC); OSTEOMYELITIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKIN INFECTION; TREATMENT DURATION; WOUND INFECTION;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CREATINE KINASE; DAPTOMYCIN; DRUG ADMINISTRATION SCHEDULE; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84882437680     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00526-13     Document Type: Article

References (41)

1. Biedenbach DJ, Moet GJ, Jones RN. 2004. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn. Microbiol. Infect. Dis. 50:59-69.
2. Carmeli Y, Eliopoulos G, Mozaffari E, Samore M. 2002. Health and economic outcomes of vancomycin-resistant enterococci. Arch. Intern. Med. 162:2223-2228.
3. Bhavnani SM, Drake JA, Forrest A, Deinhart JA, Jones RN, Biedenbach DJ, Ballow CH. 2000. A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and-susceptible enterococcal bacteremia. Diagn. Microbiol. Infect. Dis. 36: 145-158.
4. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, Fridkin SK. 2008. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect. Control Hosp. Epidemiol. 29:996-1011.
5. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39:309-317.
6. Pharmacia & Upjohn Co. 2012. Linezolid (Zyvox) package insert. Pharmacia & Upjohn Co, Division of Pfizer Inc, New York, NY.
7. Chong YP, Lee SO, Song EH, Lee EJ, Jang EY, Kim SH, Choi SH, Kim MN, Jeong JY, Woo JH, Kim YS. 2010. Quinupristin-dalfopristin versus linezolid for the treatment of vancomycin-resistant Enterococcus faecium bacteraemia: efficacy and development of resistance. Scand. J. Infect. Dis. 42:491-499.
8. Raad I, Hachem R, Hanna H, Afif C, Escalante C, Kantarjian H, Rolston K. 2004. Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections. J. Antimicrob. Chemother. 53:646-649.
9. Pogue JM, Paterson DL, Pasculle AW, Potoski BA. 2007. Determination of risk factors associated with isolation of linezolid-resistant strains of vancomycin-resistant Enterococcus. Infect. Control Hosp. Epidemiol. 28: 1382-1388.
10. Hachem RY, Hicks K, Huen A, Raad I. 2003. Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients. Clin. Infect. Dis. 37:e8-e11.
11. Baddour LM, Wilson WR, Bayer AS, Fowler VG, Jr, Bolger AF, Levison ME, Ferrieri P, Gerber MA, Tani LY, Gewitz MH, Tong DC, Steckelberg JM, Baltimore RS, Shulman ST, Burns JC, Falace DA, Newburger JW, Pallasch TJ, Takahashi M, Taubert KA. 2005. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 111: e394-e434.
12. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. 2004. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin. Infect. Dis. 38:1673-1681.
13. Fowler VG, Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fatkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE. 2006. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 355:653-665.
14. Rose WE, Rybak MJ, Kaatz GW. 2007. Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. J. Antimicrob. Chemother. 60:334-340.
15. Cubist Pharmaceuticals, Inc. 2012. Daptomycin (Cubicin) package insert. Cubist Pharmaceuticals, Inc, Lexington, MA.
16. Akins RL, Rybak MJ. 2001. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 45:454-459.
17. Segreti JA, Crank CW, Finney MS. 2006. Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients. Pharmacotherapy 26:347-352.
18. Levine DP, Lamp KC. 2007. Daptomycin in the treatment of patients with infective endocarditis: experience from a registry. Am. J. Med. 120:S28-S33.
19. Kelesidis T, Humphries R, Uslan DZ, Pegues DA. 2011. Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians. Clin. Infect. Dis. 52:228-234.
20. Moise PA, Hershberger E, Amodio-Groton MI, Lamp KC. 2009. Safety and clinical outcomes when utilizing high-dose ( or 8 mg/kg) daptomycin therapy. Ann. Pharmacother. 43:1211-1219.
21. Kullar R, Davis SL, Levine DP, Zhao JJ, Crank CW, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ. 2011. High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study. Pharmacotherapy 31:527-536.
22. Mohr JF, Friedrich LV, Yankelev S, Lamp KC. 2009. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE). Int. J. Antimicrob. Agents 33: 543-548.
23. King EA, McCoy D, Desai S, Nyirenda T, Bicking K. 2011. Vancomycinresistant enterococcal bacteraemia and daptomycin: are higher doses necessary? J. Antimicrob. Chemother. 66:2112-2118.
24. Gallagher JC, Perez ME, Marino EA, LoCastro LG, Abrardo LA, Mac-Dougall C. 2009. Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients. Pharmacotherapy 29:792-799.
25. Lodise TP, McKinnon PS, Tam VH, Rybak MJ. 2002. Clinical outcomes for patients with bacteremia caused by vancomycin-resistant enterococcus in a level 1 trauma center. Clin. Infect. Dis. 34:922-929.
26. Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG, Jr, Ryan T, Bashore T, Corey GR. 2000. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin. Infect. Dis. 30:633-638.
27. Lew DP, Waldvogel FA. 2004. Osteomyelitis. Lancet 364:369-379.
28. Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing, 22nd informational supplement. CLSI document M100-S20. CLSI, Wayne, PA.
29. Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. 2010. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin. Infect. Dis. 50:1568-1574.
30. Shay DK, Maloney SA, Montecalvo M, Banerjee S, Wormser GP, Arduino MJ, Bland LA, Jarvis WR. 1995. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J. Infect. Dis. 172:993-1000.
31. Lucas GM, Lechtzin N, Puryear DW, Yau LL, Flexner CW, Moore RD. 1998. Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes. Clin. Infect. Dis. 26:1127-1133.
32. Crank CW, Scheetz MH, Brielmaier B, Rose WE, Patel GP, Ritchie DJ, Segreti J. 2010. Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: a retrospective, multicenter, cohort study. Clin. Ther. 32:1713-1719.
33. Mave V, Garcia-Diaz J, Islam T, Hasbun R. 2009. Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid? J. Antimicrob. Chemother. 64:175-180.
34. Rand KH, Houck H. 2004. Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci. J. Antimicrob. Chemother. 53:530-532.
35. Sakoulas G, Bayer AS, Pogliano J, Tsuji BT, Yang SJ, Mishra NN, Nizet V, Yeaman MR, Moise PA. 2012. Ampicillin enhances daptomycin-and cationic host defense peptide-mediated killing of ampicillin-and vancomycin-resistant Enterococcus faecium. Antimicrob. Agents Chemother. 56:838-844.
36. Moise PA, Lamp KC, DePestel DD, Yoon MJ, Zervos MJ. 2012. Daptomycin (D) with or without concomitant beta-lactams (BL) for vancomycin-resistant Enterococcus (VRE) bacteremia, poster K276. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA, 9 to 12 September 2012.
37. De Rosa FG, Mollaretti O, Cometto C, Pagani N, Montrucchio C, Di Perri G. 2009. Early experience with high-dosage daptomycin for prosthetic infections. Clin. Infect. Dis. 49:1772-1773.
38. Katz DE, Lindfield KC, Steenbergen JN, Benziger DP, Blackerby KJ, Knapp AG, Martone WJ. 2008. A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria. Int. J. Clin. Pract. 62:1455-1464.
39. Figueroa DA, Mangini E, Amodio-Groton M, Vardianos B, Melchert A, Fana C, Wehbeh W, Urban CM, Segal-Maurer S. 2009. Safety of highdose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin. Infect. Dis. 49:177-180.
40. Durante-Mangoni E, Casillo R, Bernardo M, Caianiello C, Mattucci I, Pinto D, Agrusta F, Caprioli R, Albisinni R, Ragone E, Utili R. 2012. High-dose daptomycin for cardiac implantable electronic device-related infective endocarditis. Clin. Infect. Dis. 54:347-354.
41. Rege S, Mohr J, Lamp KC, Yoon M, Lindfield KC. 2013. Safety of daptomycin in patients completing more than 14 days of therapy: results from the Cubicin((R)) Outcomes Registry and Experience. Int. J. Antimicrob. Agents 41:421-425.